Oncology Business Management | Specialty

Optimizing the Upfront Treatment of mRCC

March 19th 2014

Cytoreductive Nephrectomy in Untreated Metastatic RCC

March 19th 2014

Frontline Treatment of Poor-Risk mRCC

March 19th 2014

Treatment of Metastatic Non-Clear Cell RCC

March 19th 2014

Introduction: Multidisciplinary Frontline Treatment of mRCC

March 19th 2014

Health Information Exchanges: Some Community Practices Are Benefitting, Many Are Not

March 19th 2014

Electronic health information exchange (HIE) continues to grow, but only in certain areas of the country and only within certain health systems and practices

Dr. Schneiderman on Cancer Drugs and Futility Policies

March 18th 2014

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses futility policies in relation to cancer drugs.

AHRQ Report Says Evaluating Survivorship Programs Difficult Because of 'Idiosyncrasies'

March 18th 2014

Efforts to evaluate cancer survivorship programs are a daunting task according to a technical brief issued by the Agency for Healthcare Research and Quality.

Amended SGR Bill Passes House, But Senate Approval Doubtful

March 17th 2014

After months of wrangling, a call for a vote by House Majority Leader Eric Cantor on an amended version of the Sustainable Growth Rate (SGR) Repeal and Medicare Provider Payment Modernization Act of 2014 (H.R. 4015).

Study: Information and Financial Losses Expected With ICD-10 Transition

March 13th 2014

Converting from ICD-9 to ICD-10 will result in information and financial losses to providers, report researchers from the University of Illinois at Chicago

FDA Tells Direct-to-Consumer Genetic Testing Company to Halt Marketing

March 12th 2014

Federal regulators have ordered the direct-to-consumer genetic testing company 23andMe to stop marketing its saliva-based test without necessary approvals as a medical device

FDA Asks Geron to Halt Imetelstat Development

March 12th 2014

The FDA has placed a full clinical hold on the development of the investigational telomerase inhibitor imetelstat following concerns over consistent low-grade liver function test (LFT) abnormalities

The Promise of ACOs and Bundled Payments Remains Cloudy

March 12th 2014

Evidence that demonstrates how best to implement newer value-based purchasing (VBP) programs like accountable care organizations (ACOs) and bundled payments is lacking

ASCO Presses for Payment Fix, Details Pressures on System

March 11th 2014

The US cancer care system is faced with increasing cuts to Medicare payments, the prospect of a dramatic increase in the number of patients with cancer, and proportionately fewer oncology specialists to treat them.

ASCO Report Says More Practices Using Advanced Practice Providers

March 11th 2014

More oncology practices are looking to advanced practice nurses and other non-physician providers to meet the needs of their cancer patients.

For Hospitals and Clinics, Spending on Anticancer Medication Moderates in 2014

March 7th 2014

New research suggests that spending on anticancer agents is moderating, going against national trends that suggest an uptick in the US prescription drug expenditures this year.

Oncology Practices Face the Biggest Change in Coding Since the Computer-ICD-10

March 5th 2014

Set for full rollout on October 1, the much delayed 10th revision of the International Statistical Classification of Diseases and Related Health Problems is probably the biggest revision to medical coding and billing since computerized medical coding and billing practices began decades ago.

Patient Relationship Management as Seen Through the Revenue Cycle

March 5th 2014

With the adoption of a patient engagement initiative, Gwinnett Medical Center in Atlanta was able to improve the billing experience for 86% of patients surveyed.

Repealing Sustainable Growth Rate Would Cost $138 Billion Over 10 Years

March 4th 2014

Repealing the sustainable growth rate (SGR) formula, a mechanism Congress enacted in 1997 to limit Medicare costs, is going to leave taxpayers with a bill of $60 billion from 2014 through 2019, and a total of $138 billion through 2024.

Peregrine's Lead Agent Receives FDA Fast Track Designation for NSCLC

March 4th 2014

Bavituximab, Peregrine Pharmaceuticals' lead clinical immunotherapeutic candidate, received Fast Track designation from the FDA to kick off 2014.